Kairos Pharma, LTD. - Form 8-K Summary
Business Context and Reporting Period
Company: Kairos Pharma, LTD.
Filing Date: July 15, 2025
Reporting Period: Current Report (Item 8.01 Other Events)
Business Focus: Biopharmaceutical company developing ENV-105 (carotuximab), a first-in-class CD105 antagonist.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding clinical trial results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Updates
- Event: Announcement of positive interim safety results from the Phase 2 clinical trial of ENV-105 in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial Status: Interim safety analysis based on the first ten enrolled patients.
- Combination Therapy: ENV-105 was administered with standard of care hormone therapy (apalutamide).
- Safety Findings:
- The drug was well tolerated.
- No dose-limiting toxicities or unexpected adverse events were reported.
- No Grade 3 or 4 toxicities were observed.
- Treatment-related side effects were manageable with standard supportive care.
Guidance, Outlook, and Risks
Management Commentary: The Company highlighted the favorable safety profile of ENV-105 in combination with apalutamide, noting the absence of severe toxicities in the initial cohort.
Risks and Contingencies: The filing includes standard disclaimers stating that the information is furnished and not "filed" under Section 18 of the Exchange Act, and shall not be deemed incorporated by reference into other filings. No specific forward-looking financial guidance or new risk factors were disclosed in this document.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed clinical data beyond the summary provided.
- Confirm the total enrollment size and timeline for the Phase 2 trial to assess the significance of the interim data from only ten patients.
- Review the Company's most recent 10-K or 10-Q filings for current cash runway and liquidity status, as this 8-K contains no financial data.
- Monitor for future updates on efficacy endpoints, as this report focuses solely on safety results.